
107.83 Delayed Data As of 3:59pm ET | ![]() Today’s Change | 78.71 Today|||52-Week Range 122.16 | -3.72% Year-to-Date |
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck, and Glaxo May 20 / Zacks.com - Paid Partner Content | Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod May 16 / Zacks.com - Paid Partner Content |
Is Perrigo a Buy After Reporting Q1 Earnings? May 20 / StockNews.com - Paid Partner Content | How Novo Nordisk Will Protect Insulin Sales May 12 / MotleyFool.com - Paid Partner Content |
4 Large Drug Stocks to Watch as the Industry Recovers May 19 / Zacks.com - Paid Partner Content |
Previous close | 107.75 |
Today’s open | 107.95 |
Day’s range | 107.29 - 108.43 |
Volume | 823,702 |
Average volume (3 months) | 1,505,739 |
Market cap | $187.3B |
Earnings growth (last year) | +19.70% |
Earnings growth (this year) | +7.43% |
Earnings growth (next 5 years) | +14.39% |
Revenue growth (last year) | +15.27% |
P/E ratio | 34.9 |
Price/Sales | 11.53 |
Price/Book | 22.69 |
Today’s change | Today’s % change | |
---|---|---|
NVSNovartis | +1.30 | +1.45% |
AZNAstraZeneca | +0.20 | +0.30% |
BMYBristol-Myers Squibb | +0.50 | +0.66% |
MRKMerck | +0.30 | +0.32% |
Next reporting date | August 4, 2022 |
EPS forecast (this quarter) | $0.83 |
Annual revenue (last year) | $22.4B |
Annual profit (last year) | $7.6B |
Net profit margin | 33.92% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Bagsværd, Capital Region |